Human methylome studies SRP404930 Track Settings
 
LN-stem, tumor stem, tumor terminally differentiated CD8 T cells from human kidney cancer [LN, PBMC, Spleen, TDLN, Tumor]

Track collection: Human methylome studies

+  All tracks in this collection (463)

Maximum display mode:       Reset to defaults   
Select views (Help):
PMD       CpG reads ▾       AMR       HMR       CpG methylation ▾      
Select subtracks by views and experiment:
 All views PMD  CpG reads  AMR  HMR  CpG methylation 
experiment
SRX18916776 
SRX18916777 
SRX18916778 
SRX18916779 
SRX18916780 
SRX18916781 
SRX18916782 
SRX18916783 
SRX18916784 
SRX18916801 
SRX18916802 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX18916779  HMR  LN / SRX18916779 (HMR)   Schema 
hide
 Configure
 SRX18916776  CpG methylation  PBMC / SRX18916776 (CpG methylation)   Schema 
hide
 Configure
 SRX18916777  CpG methylation  PBMC / SRX18916777 (CpG methylation)   Schema 
hide
 SRX18916783  HMR  Tumor / SRX18916783 (HMR)   Schema 
hide
 Configure
 SRX18916778  CpG methylation  LN / SRX18916778 (CpG methylation)   Schema 
hide
 Configure
 SRX18916779  CpG methylation  LN / SRX18916779 (CpG methylation)   Schema 
hide
 Configure
 SRX18916780  CpG methylation  LN / SRX18916780 (CpG methylation)   Schema 
hide
 Configure
 SRX18916781  CpG methylation  Tumor / SRX18916781 (CpG methylation)   Schema 
hide
 Configure
 SRX18916782  CpG methylation  Tumor / SRX18916782 (CpG methylation)   Schema 
hide
 Configure
 SRX18916783  CpG methylation  Tumor / SRX18916783 (CpG methylation)   Schema 
hide
 Configure
 SRX18916784  CpG methylation  Tumor / SRX18916784 (CpG methylation)   Schema 
hide
 Configure
 SRX18916801  CpG methylation  Tumor / SRX18916801 (CpG methylation)   Schema 
hide
 Configure
 SRX18916802  CpG methylation  Tumor / SRX18916802 (CpG methylation)   Schema 
    

Study title: LN-stem, tumor stem, tumor terminally differentiated CD8 T cells from human kidney cancer
SRA: SRP404930
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Details
SRX18916776 PBMC 0.719 2.8 18860 1064.4 56 1753.0 13 383395.2 0.996 title: GSM6862397 Naive1_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "PBMC", "tissue": "PBMC", "cell_type": "CD8 T cell"}
SRX18916777 PBMC 0.745 2.9 20943 1132.8 66 2729.0 114 236660.4 0.996 title: GSM6862398 Naive2_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "PBMC", "tissue": "PBMC", "cell_type": "CD8 T cell"}
SRX18916778 LN 0.701 11.4 21228 2390.1 5648 12351.2 583 24830.9 0.994 title: GSM6862399 K300_LN_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "LN", "tissue": "LN", "cell_type": "CD8 T cell"}
SRX18916779 LN 0.745 12.7 26244 1506.9 9276 4852.8 566 20261.8 0.994 title: GSM6862400 K241_LN_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "LN", "tissue": "LN", "cell_type": "CD8 T cell"}
SRX18916780 LN 0.715 7.4 13909 874.9 3048 20733.7 74 75286.0 0.990 title: GSM6862401 K80_LN_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "LN", "tissue": "LN", "cell_type": "CD8 T cell"}
SRX18916781 Tumor 0.661 6.5 5040 765.0 1658 36656.4 67 107177.2 0.994 title: GSM6862402 K28_T_28_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}
SRX18916782 Tumor 0.690 11.1 17061 1835.5 7042 10307.9 268 56446.0 0.996 title: GSM6862403 K300_T_28_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}
SRX18916783 Tumor 0.726 13.3 28720 1924.2 5998 11775.1 690 16055.3 0.996 title: GSM6862404 K348_T_28_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}
SRX18916784 Tumor 0.712 8.9 14720 1069.1 3221 20026.2 153 74241.7 0.996 title: GSM6862405 K28_T_39_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}
SRX18916801 Tumor 0.678 9.5 14920 991.6 5671 12151.0 141 92259.7 0.995 title: GSM6862406 K300_T_39_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}
SRX18916802 Tumor 0.756 10.8 23034 1505.3 3898 17031.0 470 23559.8 0.994 title: GSM6862407 K348_T_39_human_methylation, Homo sapiens, Bisulfite-Seq; {"source_name": "Tumor", "tissue": "Tumor", "cell_type": "CD8 T cell"}

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.